15. May 2026
(CONNECT) The Swiss-Dutch group DSM-Firmenich with Swiss headquarters in Kaiseraugst in the canton of Aargau has entered into a strategic partnership with Medisca, a supplier of personalized medicine solutions headquartered in Montreal in the Canadian province of Quebec. As part of this agreement, Medisca will make DSM-Firmenich’s portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available on the US market for the purposes of in-house medication compounding. The aim is to expand access to ingredients manufactured under European GMP (Good Manufacturing Practice) conditions and supported by documentation standards and established quality systems, as detailed in a statement.
The in-house compounding of medications by pharmacies and US pharmaceutical firms registered with the US Food and Drug Administration is increasingly supporting more complex and heavily regulated care settings. As a result, “expectations around ingredient sourcing, consistency, and documentation continue to rise”, according to the statement. The partnership now seeks to address this growing demand by introducing pharmaceutical-grade vitamin APIs on the basis of Medisca’s proven commercial and technical model.
“Ingredient sourcing is foundational to trust and long-term success in compounding”, as Peng Li, Vice President of Strategic Partnerships at Medisca, explains in the statement, adding that: “By bringing DSM-Firmenich’s pharmaceutical-grade API portfolio into the Medisca ecosystem, we are expanding what our customers can rely on today and supporting how the industry continues to evolve”. ce/nta
